Phenotypes associated with this allele

• Allele Symbol: Plcg1^tm2Gcrp
• Allele Name: targeted mutation 2, Graham Carpenter
• Allele ID: MGI:2388142
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Plcg1^tm2Gcrp/Plcg1^tm2Gcrp	involves: 129S6/SvEvTac * C57BL/6	MGI:3629733
hm2	Plcg1^tm2Gcrp/Plcg1^tm2Gcrp	involves: 129/Sv * CD-1	MGI:3629734

Genotype
MGI:3629733

hm1

• Allelic Composition: Plcg1^tm2Gcrp/Plcg1^tm2Gcrp
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

embryonic lethality, complete penetrance ( J:39281 )

• homozygotes die at ~E9.0-E9.5; embryonic lethality is consistently observed in different genetic backgrounds, including inbred 129X1/SvJ or hybrid backgrounds 129X1/SvJ C57BL/6, 129X1/SvJ Black Swiss, and 129X1/SvJ CD-1

embryo

embryonic growth arrest ( J:39281 )

• homozygotes fail to grow and develop beyond E8.5-E9.0

embryonic growth retardation ( J:39281 )

• at E8.5, ~20% of homozygotes exhibit retarded growth and development; however, placental growth and maternal-fetal connections appear normal

• by E9.5, all homozygotes are significantly retarded in size relative to wild-type embryos

growth/size/body

embryonic growth retardation ( J:39281 )

• at E8.5, ~20% of homozygotes exhibit retarded growth and development; however, placental growth and maternal-fetal connections appear normal

• by E9.5, all homozygotes are significantly retarded in size relative to wild-type embryos

Genotype
MGI:3629734

hm2

• Allelic Composition: Plcg1^tm2Gcrp/Plcg1^tm2Gcrp
• Genetic Background: involves: 129/Sv * CD-1

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:75316 )

• homozygotes die between E9.5 and E10.5

embryo

absent visceral yolk sac blood islands ( J:75316 )

• at E9.0, homozygotes show absence of blood islands in the yolk sac

abnormal embryonic hematopoiesis ( J:75316 )

• E9.0 mutant yolk sacs or embryo bodies exhibit significantly impaired primitive erythropoiesis, as shown by loss of expression of the Ter119 erythroid progenitor marker

hematopoietic system

abnormal embryonic hematopoiesis ( J:75316 )

• E9.0 mutant yolk sacs or embryo bodies exhibit significantly impaired primitive erythropoiesis, as shown by loss of expression of the Ter119 erythroid progenitor marker

abnormal proerythroblast morphology ( J:75316 )

• in vitro, CFU-E and BFU-E assays indicate that E8.0-E8.5 mutant yolk sacs or embryo bodies show a near absence of erythroid progenitors while formation of non-erythroid granulocyte/macrophage colonies remains unaffected

cardiovascular system

abnormal vascular endothelial cell development ( J:75316 )

• at E8.5, homozygotes display significantly impaired endothelial and hematopoietic development, as shown by complete loss of FLT1 expression in the yolk sac, and significantly reduced FLT1 expression in the embryo body

abnormal vasculogenesis ( J:75316 )

• at E8.5, homozygotes display significantly reduced vasculogenesis, as shown by loss of expression of the endothelial marker PECAM1 in vessels of the yolk sac, allantois, and embryo body